Advertisement

Inhibition of Amine Oxidases by Nitrofuran Derivatives: Possible Structure-Activity Relations and Criteria of Irreversibility

  • K. Quiring
  • D. Palm
Chapter

Summary

Four bacteriostatically active nitrofurfurylidene compounds and their respective hydrazine moieties were administered to male Wistar rats. MAO activity was measured in vivo by different methods in liver, brain, and small intestine. Inhibition of DAO activity was determined in small intestine of rats and, in in-vitro experiments, in a partially purified pig kidney enzyme preparation.

It is stated that, inter alia, accordance between enzyme reactivation rate and enzyme protein turnover rate is a criterion for an irreversible MAO inhibitor.

Key-Words

Monoamine Oxidase MAO Inhibitors Nitrofurans Hydrazines Enzyme Inhibition (Irreversible) 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson, F.E., Kaminsky, D., Dubnick, B., Klutchko, S.R., Cetenko, W.A., Gylys, J., Hart, J.A.: Chemistry and pharmacology of monoamine oxidase inhibitors: hydrazine derivatives. J. med. pharm. Chem. 5, 221–230 (1962).PubMedCrossRefGoogle Scholar
  2. Buffoni, F.: Histaminase and related amine oxidases. Pharmacol. Rev. 18, 1163 to 1199 (1966).Google Scholar
  3. Conney, A.H.: Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 19, 317–366 (1967).PubMedGoogle Scholar
  4. Heim, F.: Über den Einfluß von Alkoholen auf den enzymatischen Abbau des Tyramins. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 210, 16–20 (1950).CrossRefGoogle Scholar
  5. Kobayashi, Y.: The effect of three monoamine oxidase inhibitors on human plasma monoamine oxidase activity. Biochem. Pharmacol. 15, 1287–1294 (1966).CrossRefGoogle Scholar
  6. McGrath, W.R., Horita, A.: The interaction between reversible and irreversible monoamine oxidase inhibitors. Toxicol. appl. Pharmacol. 4, 178–186 (1962).CrossRefGoogle Scholar
  7. Mondovi, B., Rotilio, G., Finazzi, A., Scioscia-Santoro, A.: Purification of pig-kidney diamine oxidase and its identity with histaminase. Biochem. J. 91, 408–415 (1964).PubMedGoogle Scholar
  8. Okuyama, T., Kobayashi, Y.: Determination of diamine oxidase activity by liquid scintillation counting. Arch. Biochem. 95, 242–250 (1961).PubMedCrossRefGoogle Scholar
  9. Palm, D., Magnus, U.: Hemmung der Monoaminoxydase und der Diaminoxydase durch Furazolidon (Furoxon®). Klin. Wschr. 46, 720–728 (1968).PubMedCrossRefGoogle Scholar
  10. Magnus, U. — Grobecker, H., Jonsson, J.: Hemmung der Monoaminoxydase durch bak-teriostatisch wirksame Nitrofuranderivate. Naunyn-Schmiedebergs Arch. Pharmak. exp. Path. 256, 281–300 (1967).CrossRefGoogle Scholar
  11. — Quiring, K., May, B., Lemmer, B., Böhle, E.: Pharmacological and biochemical criteria of MAO inhibition in animals and man. Abstr. IVth Int. Congr. Pharmacol. Basel, 1969.Google Scholar
  12. Pettinger, W.A., Soyangco, F.G., Oates, J.A.: Inhibition of monoamine oxidase in man by furazolidone. Clin. Pharmacol. Ther. 9, 442–447 (1968).PubMedGoogle Scholar
  13. Remmer, H.: Drug-induced formation of smooth endoplasmic reticulum and of drug metabolizing enzymes. Proc. Europ. Soc. for the Study of Drug Toxicity, vol. IV. Excerpta Medica International Congress Series No. 81, 1964.Google Scholar
  14. — Merker, H.J.: Effect of drugs on the formation of smooth endoplasmic reticulum and drug-metabolizing enzymes. Ann. N.Y. Acad. Sci. 123, 79–97 (1965).PubMedCrossRefGoogle Scholar
  15. Robinson, D.S., Lovenberg, W., Keiser, H., Sjoerdsma, A.: Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem. Pharmacol. 17, 109–119 (1968).PubMedCrossRefGoogle Scholar
  16. Schmutzler, W.: Studien über die Histaminase-Freisetzung beim Meerschweinchen im anaphylaktischen Schock und durch Histaminase Liberatoren. Habilitationsschr., Freiburg 1966.Google Scholar
  17. Schneider, W.C.: Intracellular distribution of enzymes. III. The oxidation of octanoic acid by rat liver fractions. J. biol. Chem. 176, 259–266 (1948).Google Scholar
  18. Stern, I.J., Hollifield, R.D., Wilk, S., Buzard, J.A.: The anti-monoamine oxidase effects of furazolidone. J. Pharmacol. exp. Ther. 156, 492–499 (1967).PubMedGoogle Scholar
  19. Wurtman, R.J., Axelrod, J.: A sensitive and specific assay for the estimation of monoamine oxidase. Biochem. Pharmacol. 12, 1439–1440 (1963).PubMedCrossRefGoogle Scholar
  20. Zeller, E.A.: Monoamine and polyamine analogues. In: Metabolic inhibitors, vol. II (eds. R.M. Hochster and J.H. Quastel), pp. 53–78. New York: Academic Press 1963.CrossRefGoogle Scholar
  21. — Barsky, J., Fouts, R., Lazanas, E.J.: Structural requirements for the inhibition of amine oxidases. Biochem. J. 60, 5 (1955).Google Scholar
  22. Zeller, V., Ramachander, G., Zeller, E.A.: Amine oxidases. XXI. A rapid method for the determination of the activity of monoamine oxidase and monoamine oxidase inhibitors. J. med. Chem. 8, 440–443 (1965).Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1969

Authors and Affiliations

  • K. Quiring
    • 1
  • D. Palm
    • 1
  1. 1.Pharmakologisches Institut der Universität6 Frankfurt a. M. 70Deutschland

Personalised recommendations